Dabrafenib in BRAFV600E mutant pilocytic astrocytoma in a pediatric patient

F. Mustansir, N. Mushtaq, A. Darbar

Research output: Contribution to journalArticlepeer-review

8 Citations (Scopus)


Pilocytic astrocytomas (PAs) are the most common pediatric central nervous system tumors. They constitute around 30% of all primary central nervous tumors in the pediatric age group. Their clinical behavior may vary but most of them are indolent and do not undergo malignant transformations compared with their adult counterparts. PAs are primarily treated with surgery and in cases of progression; chemotherapy may be needed. They usually carry a good prognosis, with a 10-year survival rate of 90%. BRAFV600E mutations have been identified in approximately 9–15% of patients with PA. These relatively high mutation frequencies in PA open avenues for treatment using targeted therapies such as BRAFV600E inhibitors (e.g., dabrafenib). There have been a few published case reports and case series showing clinical benefits with BRAF inhibitors in BRAF-positive tumors. We report a case of successful treatment of BRAFV600E immunopositive optic pathway PA in a child with dabrafenib.

Original languageEnglish
Pages (from-to)203-207
Number of pages5
JournalChild's Nervous System
Issue number1
Publication statusPublished - 1 Jan 2020


  • BRAFV600E
  • Dabrafenib treatment
  • Pilocytic astrocytoma


Dive into the research topics of 'Dabrafenib in BRAFV600E mutant pilocytic astrocytoma in a pediatric patient'. Together they form a unique fingerprint.

Cite this